These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 29727206)

  • 1. Recent preclinical and clinical advances in oligonucleotide conjugates.
    Craig K; Abrams M; Amiji M
    Expert Opin Drug Deliv; 2018 Jun; 15(6):629-640. PubMed ID: 29727206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The chemistry and biology of oligonucleotide conjugates.
    Juliano RL; Ming X; Nakagawa O
    Acc Chem Res; 2012 Jul; 45(7):1067-76. PubMed ID: 22353142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases.
    Ossipov DA
    Expert Opin Drug Deliv; 2019 Jun; 16(6):621-637. PubMed ID: 31072142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reality check: lipid-oligonucleotide conjugates for therapeutic applications.
    Goodnow RA
    Expert Opin Drug Discov; 2023 Feb; 18(2):129-134. PubMed ID: 36546308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of a splice-switching oligonucleotide by cationic polyplexes of RGD-oligonucleotide conjugate.
    Ming X; Feng L
    Mol Pharm; 2012 May; 9(5):1502-10. PubMed ID: 22497548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligonucleotide delivery: a patent review (2010 - 2013).
    Grijalvo S; Aviñó A; Eritja R
    Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands.
    Nakagawa O; Ming X; Huang L; Juliano RL
    J Am Chem Soc; 2010 Jul; 132(26):8848-9. PubMed ID: 20550198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase.
    Huggins IJ; Medina CA; Springer AD; van den Berg A; Jadhav S; Cui X; Dowdy SF
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31509944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug delivery system of therapeutic oligonucleotides.
    Asami Y; Yoshioka K; Nishina K; Nagata T; Yokota T
    Drug Discov Ther; 2016; 10(5):256-262. PubMed ID: 27890899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment-based solid-phase assembly of oligonucleotide conjugates with peptide and polyethylene glycol ligands.
    Dirin M; Urban E; Noe CR; Winkler J
    Eur J Med Chem; 2016 Oct; 121():132-142. PubMed ID: 27236069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular delivery of oligonucleotide conjugates and dendrimer complexes.
    Juliano RL
    Ann N Y Acad Sci; 2006 Oct; 1082():18-26. PubMed ID: 17145920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid conjugated oligonucleotides: a useful strategy for delivery.
    Raouane M; Desmaële D; Urbinati G; Massaad-Massade L; Couvreur P
    Bioconjug Chem; 2012 Jun; 23(6):1091-104. PubMed ID: 22372953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
    Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
    J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery systems for oligonucleotide therapeutics.
    Yu B; Zhao X; Lee LJ; Lee RJ
    AAPS J; 2009 Mar; 11(1):195-203. PubMed ID: 19296227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a future for cell-penetrating peptides in oligonucleotide delivery?
    Lee SH; Castagner B; Leroux JC
    Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled delivery of antisense oligonucleotides: a brief review of current strategies.
    Zhao X; Pan F; Holt CM; Lewis AL; Lu JR
    Expert Opin Drug Deliv; 2009 Jul; 6(7):673-86. PubMed ID: 19552611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA.
    Juliano RL
    Curr Opin Mol Ther; 2005 Apr; 7(2):132-6. PubMed ID: 15844620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications.
    Benizri S; Gissot A; Martin A; Vialet B; Grinstaff MW; Barthélémy P
    Bioconjug Chem; 2019 Feb; 30(2):366-383. PubMed ID: 30608140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP
    Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted lipid nanoparticles for antisense oligonucleotide delivery.
    Petrilli R; Eloy JO; Marchetti JM; Lopez RF; Lee RJ
    Curr Pharm Biotechnol; 2014; 15(9):847-55. PubMed ID: 25335532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.